The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...

Blockages in coronary arteries cause sudden heart attacks, leading to heart muscle damage. In contrast, heart failure is a ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

What is ALPK2, and how can it help treat heart failure? Researchers have found that this heart-specific enzyme may prevent ...

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce the risk of heart failure," the authors noted in JAMA Internal Medicine.

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...